IP Verse

Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole For Use As A Medicament - EP3977993

The patent EP3977993 was granted to Pfizer on Jan 31, 2024. The application was originally filed on Aug 31, 2015 under application number EP21203965A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3977993

PFIZER
Application Number
EP21203965A
Filing Date
Aug 31, 2015
Status
Granted And Under Opposition
Dec 29, 2023
Grant Date
Jan 31, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KELTIEOct 31, 2024KELTIEADMISSIBLE
QUIMICA SINTETICAOct 29, 2024AERAADMISSIBLE
QUIMICA SINTETICAOct 29, 2024BARDEHLE PAGENBERG SLADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5033252
DESCRIPTIONUS5052558
DESCRIPTIONUS5323907
DESCRIPTIONUS7214695
DESCRIPTIONUS8576985
OPPOSITIONEP1587821
OPPOSITIONWO2004056315
SEARCHUS7214695
SEARCHWO2013038351

Non-Patent Literature (NPL) Citations (40) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BUXBAUM, J. N.TAGOE, C. E., Ann. Rev. Med., (20000000), vol. 51, pages 543 - 569-
DESCRIPTION- COLON, W.KELLY, J. W., Biochemistry, (19920000), vol. 31, pages 8654 - 60-
DESCRIPTION- JACOBSON, D. R. et al., N. Engl. J. Med., (19970000), vol. 336, pages 466 - 73-
DESCRIPTION- KELLY, J. W, Curr. Opin. Struct. Biol., (19960000), vol. 6, pages 11 - 7-
DESCRIPTION- LIU, K. et al., Nat. Struct. Biol., (20000000), vol. 7, pages 754 - 7-
DESCRIPTION- SARAIVA, M. J. et al., J. Clin. Invest., (19850000), vol. 76, pages 2171 - 7-
DESCRIPTION- SARAIVA, M., J. Hum. Mutat., (19950000), vol. 5, pages 191 - 6-
DESCRIPTION- WESTERMARK, P. et al., Proc. Natl. Acad. Sci. U. S. A., (19900000), vol. 87, pages 2843 - 5-
OPPOSITION- Anonymous, "2.9.33. - Characterisation of Crystalline and Partially Crystalline Solids by X-Ray Powder Diffraction (XRPD)", European Pharmacopeia 7.0, (20090101), pages 301 - 305, XP055582946-
OPPOSITION- Anonymous, "Angewandte Chemie - Supporting Information for Angew. Chem. Int. Ed. Z51179", Wiley-VCH, (20030101), pages 1 - 24, Wiley-VCH, URL: https://application.wiley-vch.de/contents/jc_2002/2003/z51179_s.pdf, (20241218), XP093235419-
OPPOSITION- Anonymous, "Vyndaqel International non-proprietary name: tafamidis - EMEA/H/C/002294/X/0049/G", European medicines agency - science medicines health, (20191212), pages 1 - 95, XP093235434-
OPPOSITION- Bauer K.H., "Passage; Kapitel 7 - Biopharmazie", Bauer K.H., Bauer, Lehrbuch der Pharmazeutischen Technologie- Mit einer Einführung in die Biopharmazie, Wissenschaftliche Verslagsgesellschaft mbH, Stuttgart , (20060101), pages 214 - 217, ISBN 3-8047-2222-9, XP055436785-
OPPOSITION- Bavin Mike , "Polymorphism in Process Development", Chemistry & Industry, (19890821), pages 527 - 529, XP093192606-
OPPOSITION- D11 - Datasheet for the decision of 14 January 2020 - T 41/17 -
OPPOSITION- D14 - Declaration of Kapildev Arora - European Patent No. 3 191461 B1 Pfizer Inc-
OPPOSITION- D15 - Declaration of Hahdi Perfect - European Patent No. 3 191461 B1 Pfizer Inc-
OPPOSITION- D16 - Decision T 392/06 - Datasheet for the decision of 22 October 2008-
OPPOSITION- D17 - 2nd declaration of Giuseppe Barreca, dated 29 March 2023-
OPPOSITION- D21 - Proprietor’s letter dated 19 February 2019-
OPPOSITION- D3 - T 2007/11 - Datasheet for the decision of 7 October 2014-
OPPOSITION- D6 - Declaration by Giuseppe Barreca concerning the reproduction of examples according to D4 and D-
OPPOSITION- D7 - The “Perfect report”, submitted by the proprietor during Examination (19.2.2019)-Synthesis of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole-
OPPOSITION- D8 - The “Jensen report”, submitted by the proprietor during Examination (19.2.2019) - XRD analysis of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole-
OPPOSITION- D9 - T 777/08 - Datasheet for the decision of 24 May 2011-
OPPOSITION- Ema Chmp, "Vyndaqel - tafamidis meglumine", Assessment report EMEA/H/C/002294, (20110922), pages 1 - 85, XP055952004-
OPPOSITION- Hancock Bruno C, Sheri L. Shamblin & George Zografi , "Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures", Pharmaceutical Research, (19950601), vol. 12, no. 6, pages 799 - 806, XP093138456-
OPPOSITION- H.G. Brittain, "X-Ray Diffraction", H.G. Brittain, Anonymous, Polymorphism in Pharmaceutical Solids, Informa Healthcare , (20090101), pages 333 - 338, XP055587170-
OPPOSITION- L. Yu, "Amorphous pharmaceutical solids: preparation, characterisation and stabilisation", Advanced Drug Delivery Reviews, (20010101), vol. 48, pages 27 - 42, XP055721630-
OPPOSITION- L. Addadi; S. Raz; S. Weiner, "Taking Advantage of Disorder: Amorphous Calcium Carbonate and Its Roles in Biomineralization", Advanced Materials, DE , (20030616), vol. 15, no. 12, doi:10.1002/adma.200300381, ISSN 0935-9648, pages 959 - 970, XP071804836
OPPOSITION- Hossein Razavi , Satheesh K Palaninathan, Evan T Powers, R Luke Wiseman, Hans E Purkey, Nilofar N Mohamedmohaideen, Songpon Deechongkit, Kyle P Chiang, Maria T A Dendle, James C Sacchettini, Jeffery W Kelly, "Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, evaluation, and Mechanism of Action", Angewandte Chemie International Edition, Hoboken, USA, (20030101), vol. 42, doi:10.1002/anie.200351179, ISSN 1433-7851, pages 2758 - 2761, XP002322019
OPPOSITION- Alfons Grunenberg, "Polymorphie und Thermische Analyse pharmazeutischer Wirkstoffe", Pharmazie in unserer Zeit, (19970101), vol. 26, no. 5, doi:10.1002/pauz.19970260506, pages 224 - 231, XP055745450
OPPOSITION- Craig DQ, Royall PG, Kett VL, Hopton ML., "The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems", International Journal of Pharmaceutics, AMSTERDAM, NL, (19990315), vol. 179, no. 2, doi:10.1016/S0378-5173(98)00338-X, ISSN 0378-5173, pages 179 - 207, XP009100532
OPPOSITION- Hancock Bruno C; George Zografi, "Characteristics and Significance of the Amorpous State in Pharmaceutical Systems", Journal of Pharmaceutical Sciences, (19970101), vol. 86, no. 1, doi:10.1021/js9601896, ISSN 0022-3549, pages 1 - 12, XP002286839
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, Berlin/Heidelberg, (19950701), vol. 12, no. 07, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954, XP000996386
OPPOSITION- Hiroyuki Imaizumi , Naoki Nambu , Tsuneji nagai, "Stability and Several Physical Properties of Amorphous and Crystalline Forms of Indomethacin", Chemical and Pharmaceutical Bulletin, JP , (19800925), vol. 28, no. 9, doi:10.1248/cpb.28.2565, ISSN 0009-2363, pages 2565 - 2569, XP001206577
OPPOSITION- Masciocchi Norberto, Abbinante Vincenzo Mirco, Zambra Marco, Barreca Giuseppe, Zampieri Massimo, "Thermal and Structural Characterization of Two Crystalline Polymorphs of Tafamidis Free Acid", Molecules, CH , (20220101), vol. 27, no. 21, doi:10.3390/molecules27217411, ISSN 1420-3049, pages 1 - 13, XP093235437
SEARCH[ ] - Razavi H et al., "Supporting Information for Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, evaluation, and Mechanism of Action", Angew Chem Int. Ed., vol. 42, (20030101), URL: http://www.wiley-vch.de/contents/jc_2002/2003/z51179_s.pdf, (20151019), XP055221854 [ ] * pages s7-s8; compound 19 *-
SEARCH- RAZAVI H ET AL, "Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, evaluation, and Mechanism of Action", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, (20030101), vol. 42, doi:10.1002/ANIE.200351179, ISSN 1433-7851, pages 2758 - 2761, XP002322019 [A] 1-11 * the whole document *
SEARCH- S. C. PENCHALA ET AL, "AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20130528), vol. 110, no. 24, doi:10.1073/pnas.1300761110, ISSN 0027-8424, pages 9992 - 9997, XP055221811 [A] 1-11 * page 9996 *
SEARCH[ ] - S. C. PENCHALA ET AL, "Supplementary Information for AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20130611), vol. 110, no. 24, doi:10.1073/pnas.1300761110, ISSN 0027-8424, pages 9992 - 9997, XP055221845 [ ] * page 12 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents